Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Must Have Compelling Reason To Deny Advisory Review Request- PhRMA

Executive Summary

FDA must present a compelling argument for denial of a sponsor's request for an advisory committee review of an unresolved scientific dispute with the agency, the Pharmaceutical Research & Manufacturers of America said in comments on FDA's draft guidance for formal dispute resolution.

You may also be interested in...

FDA Dispute Resolution Rules May Not Supplant Informal Appeals - Morrison

Industry continues to exercise informal appeals rather than official dispute resolution procedures to address disagreements with FDA, Center for Drug Evaluation & Research Ombudsman Jim Morrison said.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts